Home > Search Results

Results: 1 to 20 of 66


This study found that, given the current evidence, a negative tuberculin skin test (TST) (≥ 5 mm) followed by a QuantiFERON®-TB Gold-In-Tube (QFT-GIT) test for children, a negative QFT-GIT test followed by a TST (≥ 5 mm) test for the immunocompromised population and a TST (≥ 5 mm) test for recent arrivals were the most cost-effective strategies for diagnosing latent tuberculosis infection that progresses to active tuberculosis.

Health Technology Assessment - NIHR Journals Library.

Version: May 2016

Cancer is an important condition, both in terms of the number of people affected and the impacts on those people and the people close to them. Around one third of a million new cancers are diagnosed annually in the UK, across over 200 different cancer types. Each of these cancer types has different presenting features, though there may be overlap. More than one third of the population will develop a cancer in their lifetime. Although there have been large advances in treatment and survival, with a half of cancer sufferers now living at least ten years after diagnosis, it remains the case that more than a quarter of all people alive now will die of cancer.

NICE Guideline - National Collaborating Centre for Cancer (UK).

Version: June 2015

A wide variety of wound care products are available for clinicians to choose from when treating chronic wounds. Many of these products are said to mimic or substitute for some aspect of the skin's structure and function to promote healing and wound closure. The materials used to produce these products may be derived from human or animal tissue and may undergo extensive or minimal processing to make the finished product. The extent of processing and the source of the material used in the product also determines what regulatory pathway may be required before the product can be marketed. CMS requested this report on the types of wound care products that are commonly referred to as “skin substitutes” and on the regulatory pathways required for the different types of products. For this report, we have not created a definition for a skin substitute product. Instead we used the products listed under CMS codes Q4101 to Q4122 as a starting point and looked for similar products listed in the U.S. Food and Drug Administration (FDA) product codes to generate a list of products. We included only those products indicated for chronic wounds. We note that FDA does not refer to any product or class of products as “skin substitutes,” and we are not proposing an official classification system.

Technology Assessment Report - Agency for Healthcare Research and Quality (US).

Version: December 18, 2012

The Consolidated guidelines on HIV testing services bring together existing guidance relevant to the provision of HIV testing services (HTS) and addresses issues and elements for effective delivery of HTS that are common in a variety of settings, contexts and diverse populations.

World Health Organization.

Version: July 2015

Multiplex allergen testing may change clinicians’ views on patients’ management, but there is no evidence of its impact on patients’ outcomes and it is unlikely to be cost-saving.

Health Technology Assessment - NIHR Journals Library.

Version: September 2016

Atopic eczema (atopic dermatitis) is a chronic inflammatory itchy skin condition that develops in early childhood in the majority of cases. It is typically an episodic disease of exacerbation (flares, which may occur as frequently as two or three per month) and remissions, except for severe cases where it may be continuous. Certain patterns of atopic eczema are recognised. In infants, atopic eczema usually involves the face and extensor surfaces of the limbs and, while it may involve the trunk, the napkin area is usually spared. A few infants may exhibit a discoid pattern (circular patches). In older children flexural involvement predominates, as in adults. Diagnostic criteria are discussed in Chapter 3. As with other atopic conditions, such as asthma and allergic rhinitis (hay fever), atopic eczema often has a genetic component. In atopic eczema, inherited factors affect the development of the skin barrier, which can lead to exacerbation of the disease by a large number of trigger factors, including irritants and allergens. Many cases of atopic eczema clear or improve during childhood while others persist into adulthood, and some children who have atopic eczema `will go on to develop asthma and/or allergic rhinitis; this sequence of events is sometimes referred to as the ‘atopic march’. The epidemiology of atopic eczema is considered in Chapter 5, and the impact of the condition on children and their families/caregivers is considered in Sections 4.2 and 4.3.

NICE Clinical Guidelines - National Collaborating Centre for Women's and Children's Health (UK).

Version: December 2007

The microbial causes of pneumonia vary according to its origin and the immune constitution of the patient. Pneumonia is classified into community-acquired pneumonia (CAP), hospital-acquired pneumonia (HAP) and pneumonia in the immunocompromised. The guideline development process is guided by its scope - published after stakeholder consultation. This guideline does not cover all aspects of pneumonia, but focuses on areas of uncertainty or variable practice and those considered of greatest clinical importance. Best practice guidance on the diagnosis and management of CAP and HAP is offered, based on systematic analysis of clinical and economic evidence with the aim of reducing mortality and morbidity from pneumonia and maximising resources.

NICE Clinical Guidelines - National Clinical Guideline Centre (UK).

Version: December 2014

The objectives are: (1) to assess the published research evidence on the clinical effectiveness, harms, cost-effectiveness, and associated patients' preferences and values of screening for hepatitis C virus (HCV) infection in asymptomatic, non-pregnant, treatment-naive adults; and (2) to assess the published research evidence on the ability of available antibody (Ab) and antigen (Ag) screening tests to identify people in the general population with chronic HCV infection.

CADTH Health Technology Assessment - Canadian Agency for Drugs and Technologies in Health.

Version: March 2017

This report will review evidence investigating the uncertainty surrounding the clinical effectiveness of vitamin D supplementation for both the prevention and treatment of multiple sclerosis (MS) in adults.

Rapid Response Report: Summary with Critical Appraisal - Canadian Agency for Drugs and Technologies in Health.

Version: March 10, 2016

Multiple sclerosis (MS) is an acquired chronic immune-mediated inflammatory condition of the central nervous system (CNS), affecting both the brain and spinal cord. It affects approximately 100,000 people in the UK. It is the commonest cause of serious physical disability in adults of working age.

NICE Clinical Guidelines - National Clinical Guideline Centre (UK).

Version: October 2014

Testing and diagnosis of hepatitis B (HBV) and C (HCV) infection is the gateway for access to both prevention and treatment services, and is a crucial component of an effective response to the hepatitis epidemic. Early identification of persons with chronic HBV or HCV infection enables them to receive the necessary care and treatment to prevent or delay progression of liver disease. Testing also provides an opportunity to link people to interventions to reduce transmission, through counselling on risk behaviours and provision of prevention commodities (such as sterile needles and syringes) and hepatitis B vaccination.

World Health Organization.

Version: February 2017

Study found that reflex testing for Lynch syndrome in newly diagnosed colorectal cancer patients aged under 50 years is cost-effective, and that such testing may also be cost-effective in newly diagnosed patients aged under 60 or under 70 years. However, the results are subject to uncertainty due to a number of parameters.

Health Technology Assessment - NIHR Journals Library.

Version: September 2014

This study aims to determine the test accuracy and cost-effectiveness of the sentinel lymph node (SLN) biopsy with 99mTc and/or blue dye compared with inguinofemoral lymphadenectomy or clinical follow-up for test negatives in vulval cancer. A sensitive and specific combined metastatic SLN detection test and information on generic quality of life in vulval cancer is urgently required.

Health Technology Assessment - NIHR Journals Library.

Version: December 2013

Microsatellite instability and immunohistochemistry will identify most cases of Lynch syndrome in colorectal cancer but there is no high-quality evidence that screening improves long-term outcomes.

Health Technology Assessment - NIHR Journals Library.

Version: September 2017

This guideline makes recommendations on the prevention, diagnosis and management of latent and active tuberculosis (TB), including both drug susceptible and drug resistant forms of the disease. It covers the organisation of relevant TB services. It relates to activities undertaken in any setting in which NHS or public health services for TB are received, provided or commissioned in the public, private and voluntary sectors.

NICE Guideline - Internal Clinical Guidelines Team (UK).

Version: January 2016

This guideline covers bacterial meningitis and meningococcal septicaemia, focusing on management of these conditions in children and young people aged younger than 16 years in primary and secondary care, and using evidence of direct relevance to these age groups where available.

NICE Clinical Guidelines - National Collaborating Centre for Women's and Children's Health (UK).

Version: 2010

The guideline covers care provided by healthcare professionals who have direct contact with and make decisions about the care of people with chronic fatigue syndrome/myalgic encephalomyelitis (or encephalopathy) (CFS/ME). It covers care provided in primary and secondary care, and in specialist centres/teams.

NICE Clinical Guidelines - National Collaborating Centre for Primary Care (UK).

Version: August 2007

These guidelines cover most aspects of nutrition support in adult patients (>18 years) who are either malnourished or are at ‘risk’ of malnutrition. In some cases specific guidance related to patients in specific care settings or with specific diseases has been provided but in general the guidance is applicable to patients whatever their setting (hospital or community) or disease. The guideline therefore includes: information on the prevalence of malnutrition and the benefits of good nutrition; guidance on the appropriate forums for the organisation of nutrition support in all settings; guidance on who should be screened for malnutrition and when, along with the criteria for consideration when assessing patients’ nutritional status; the general indications for nutrition support together with ethical and legal considerations that may arise; guidance on the process and special considerations required to prescribe nutrition support and details information on the important parameters to monitor for patients receiving nutrition support; detailed guidance on the administration of oral, enteral and parenteral nutrition including; the appropriate types of access for enteral and parenteral nutrition and the optimum mode of delivering these; specific guidance on the management of providing nutrition support to patients with dysphagia; issues to consider for patients receiving enteral and parenteral nutrition support in the community; issues arising for patients and their carers.

NICE Clinical Guidelines - National Collaborating Centre for Acute Care (UK).

Version: February 2006

This guideline has been developed to advise on psychosocial interventions for drug misuse. The guideline recommendations have been developed by a multidisciplinary team of healthcare professionals, service users, a carer and guideline methodologists after careful consideration of the best available evidence. It is intended that the guideline will be useful to clinicians and service commissioners in providing and planning high-quality care for people who misuse drugs while also emphasising the importance of the experience of care for people who misuse drugs and their carers.

NICE Clinical Guidelines - National Collaborating Centre for Mental Health (UK).

Version: 2008

Jaundice is one of the most common conditions requiring medical attention in newborn babies. Approximately 60% of term and 80% of preterm babies develop jaundice in the first week of life, and about 10% of breastfed babies are still jaundiced at 1 month of age. In most babies with jaundice thevre is no underlying disease, and this early jaundice (termed ‘physiological jaundice’) is generally harmless. However, there are pathological causes of jaundice in the newborn, which, although rare, need to be detected. Such pathological jaundice may co-exist with physiological jaundice.

NICE Clinical Guidelines - National Collaborating Centre for Women's and Children's Health (UK).

Version: May 2010

Systematic Reviews in PubMed

See all (7)...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...